Award-winning sepsis project gets $13M and a shot at reopening an R&D avenue as FDA pitches out old gold standard
As chair of the British Heart Foundation’s translational awards committee, David Grainger was powerfully attracted to some research that Glasgow University professor James Leiper was doing on a common symptom of septic shock, a major killer that is responsible for more than a quarter million deaths in the US each year.
That was good for an award.
But now Grainger, a partner at Medicxi, has followed through with an $13 million venture round to create a virtual company called Critical Pressure that could take this asset through early-stage studies and into the hands of commercial buyer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
